Cargando…

Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis

Background: Adjuvant sorafenib may enhance the efficacy of transarterial radioembolization with yttrium-90 in hepatocellular carcinoma patients. The aim of this study is to assess the efficacy and safety of radioembolization plus sorafenib in comparison to radioembolization alone. Methods: Out of 17...

Descripción completa

Detalles Bibliográficos
Autores principales:	Facciorusso, Antonio, Bargellini, Irene, Cela, Marina, Cincione, Ivan, Sacco, Rodolfo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226318/ https://www.ncbi.nlm.nih.gov/pubmed/32272656 http://dx.doi.org/10.3390/cancers12040897

Ejemplares similares

Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
por: Öcal, Osman, et al.
Publicado: (2022)

Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma
por: Lee, Hannah M., et al.
Publicado: (2023)

Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib
por: Rana, Nitesh, et al.
Publicado: (2013)

Radioembolization and the Dynamic Role of (90)Y PET/CT
por: Pasciak, Alexander S., et al.
Publicado: (2014)

Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma
por: Lee, Victor Ho-Fun, et al.
Publicado: (2015)

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
por: Kallini, Joseph Ralph, et al.
Publicado: (2016)

History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma
por: Saini, Aman, et al.
Publicado: (2019)

Yttrium-90 Radioembolization as the Major Treatment of Hepatocellular Carcinoma
por: Yu, Chun-Yen, et al.
Publicado: (2023)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
por: Teyateeti, Ajalaya, et al.
Publicado: (2020)

Side Effects of Yttrium-90 Radioembolization
por: Riaz, Ahsun, et al.
Publicado: (2014)

Transarterial Radioembolization (TARE) Agents beyond (90)Y-Microspheres
por: Bouvry, C., et al.
Publicado: (2018)

Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases
por: Tsang, Erica S., et al.
Publicado: (2020)

Simplification of dosimetry in (90)Y-radioembolization therapy by dual planar images
por: Abuqbeitah, Mohammad, et al.
Publicado: (2022)

Single-Compartment Dose Prescriptions for Ablative (90)Y-Radioembolization Segmentectomy
por: Kappadath, Srinivas Cheenu, et al.
Publicado: (2023)

Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer
por: Puleo, Luciana, et al.
Publicado: (2022)

Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
por: Nabrinsky, Edward, et al.
Publicado: (2020)

Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis
por: Rognoni, Carla, et al.
Publicado: (2018)

Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with (90)Y microspheres
por: Yim, Sun Young, et al.
Publicado: (2014)

Temporary Reversal of Hepatoenteric Collaterals during (90)Y Radioembolization Planning and Administration
por: Habibollahi, Peiman, et al.
Publicado: (2022)

Internal dosimetry for radioembolization therapy with Yttrium‐90 microspheres
por: Fallahpoor, Maryam, et al.
Publicado: (2017)

Role of Yttrium-90 Radioembolization for Colorectal Hepatic Metastasis
por: Kim, Hyo-Cheol
Publicado: (2022)

Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib
por: Teyateeti, Ajalaya, et al.
Publicado: (2021)

Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience
por: Meyer, Carsten, et al.
Publicado: (2017)

Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma
por: Villalobos, Alexander, et al.
Publicado: (2021)

Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
por: Şener, Nur, et al.
Publicado: (2023)

Phantom validation of quantitative Y-90 PET/CT-based dosimetry in liver radioembolization
por: D’Arienzo, Marco, et al.
Publicado: (2017)

Genomic mutations and histopathologic biomarkers in Y(90) radioembolization for chemorefractory colorectal liver metastases
por: Dendy, Meaghan S., et al.
Publicado: (2018)

(90)Y Radioembolization: Telemedicine During COVID-19 Outbreak, Opportunity for Prime Time
por: Quek, Lawrence, et al.
Publicado: (2020)

Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma
por: Kaya, Neslihan Arife, et al.
Publicado: (2023)

Yttrium-90 Radioembolization of Hepatic Metastases from Colorectal Cancer
por: Raval, Mihir, et al.
Publicado: (2014)

Yttrium-90 Radioembolization: An Unusual Cause of Radiating Abdominal Pain
por: Estes, Derek J., et al.
Publicado: (2019)

Transarterial radioembolization with Yttrium-90: current status and future prospects
por: Yang, Hua-Yu, et al.
Publicado: (2020)

Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score’s prediction factor for survival?
por: Evirgen, Sami, et al.
Publicado: (2023)

Transradial versus transfemoral arterial access in Yttrium-90 microspheres radioembolization for hepatocellular carcinoma
por: Ghosh, Abheek, et al.
Publicado: (2022)

Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review
por: Alonso, J. C., et al.
Publicado: (2022)

Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study
por: Kim, Minseok Albert, et al.
Publicado: (2021)

Imaging Evaluation Following (90)Y Radioembolization of Liver Tumors: What Radiologists Should Know
por: Joo, Ijin, et al.
Publicado: (2018)

The role of (90)Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review
por: Braat, M. N. G. J. A., et al.
Publicado: (2016)

Feasibility of imaging (90)Y microspheres at diagnostic activity levels for hepatic radioembolization treatment planning
por: Kunnen, Britt, et al.
Publicado: (2020)

Factors modulating (99m)Tc‐MAA planar lung dosimetry for (90)Y radioembolization
por: Lopez, Benjamin P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n969q0t7il0vv2b3n6qduk9k2v